--- title: "首次公开募股动态：Seaport Therapeutics 增加了 IPO 的规模，并将其定价为 18 美元——处于定价区间的高端" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/284896142.md" description: "Seaport Therapeutics（SPTX），一家位于波士顿的生物科技公司，已将其首次公开募股（IPO）规模增加至 1416 万股，定价为 18.00 美元，筹集资金为 2.5488 亿美元。该股票将于 2026 年 5 月 1 日在纳斯达克交易。公司计划将筹集的资金用于其治疗重度抑郁症药物的第二阶段临床试验。按此定价，Seaport Therapeutics 的市值为 9.545 亿美元。高盛等公司是此次 IPO 的联合主承销商" datetime: "2026-05-01T12:00:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284896142.md) - [en](https://longbridge.com/en/news/284896142.md) - [zh-HK](https://longbridge.com/zh-HK/news/284896142.md) --- # 首次公开募股动态：Seaport Therapeutics 增加了 IPO 的规模，并将其定价为 18 美元——处于定价区间的高端 **Seaport Therapeutics (SPTX), a Boston-based biotech developing drugs to treat major depression, increased its IPO’s size at pricing – to 14.16 million shares – up from 11.8 million in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $254.88 million on Thursday night, April 30, 2026.** **Shares of Seaport Therapeutics are set to start trading today – Friday, May 1, 2026 – on the NASDAQ.** **Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel are the joint book-runners.** **At pricing, Seaport Therapeutics had a market cap of $954.5 million.** **Seaport Therapeutics (SPTX) intends to use the IPO’s proceeds to help fund the Phase 2 clinical trials of its leading drug candidates, GlyphAllo (SPT-300) and GlyphAgo (SPT-320), to treat major depression, including postpartum depression.** **The company is not profitable.** **(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)** **Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.** **To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.** **Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.** ### 相关股票 - [SEELQ.US](https://longbridge.com/zh-CN/quote/SEELQ.US.md) - [SEEL.US](https://longbridge.com/zh-CN/quote/SEEL.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [GS.US](https://longbridge.com/zh-CN/quote/GS.US.md) - [JPM.US](https://longbridge.com/zh-CN/quote/JPM.US.md) - [C.US](https://longbridge.com/zh-CN/quote/C.US.md) - [SF.US](https://longbridge.com/zh-CN/quote/SF.US.md) - [NDAQ.US](https://longbridge.com/zh-CN/quote/NDAQ.US.md) - [W4VR.SG](https://longbridge.com/zh-CN/quote/W4VR.SG.md) - [JPM-M.US](https://longbridge.com/zh-CN/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/zh-CN/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/zh-CN/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/zh-CN/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/zh-CN/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/zh-CN/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/zh-CN/quote/JPM-J.US.md) - [C-R.US](https://longbridge.com/zh-CN/quote/C-R.US.md) - [SF-C.US](https://longbridge.com/zh-CN/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/zh-CN/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/zh-CN/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/zh-CN/quote/SF-D.US.md) ## 相关资讯与研究 - [花旗看好催化剂与增长前景，覆盖 Ionis、Alnylam、BioMarin 并给予买入评级](https://longbridge.com/zh-CN/news/286956616.md) - [瑞银上调爵士制药评级：核心业务韧性强劲，新药 Ziihera 成增长引擎](https://longbridge.com/zh-CN/news/286920691.md) - [Scholar Rock 将出席杰富瑞全球医疗保健大会，聚焦 SMA 新药 apitegromab 关键审批](https://longbridge.com/zh-CN/news/287069556.md) - [金融产业日报 (05.20) : 全球债市抛售](https://longbridge.com/zh-CN/news/287110082.md) - [Tevogen Bio Q1 运营亏损收窄 48%，推进 AI 平台与细胞疗法管线](https://longbridge.com/zh-CN/news/287086570.md)